Terence Williams M MD, PhD

Terence Williams M MD, PhD
Res Asst ProfessorCollege of Medicinewilliams.4218@osu.edu
James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus Ohio 43210
Phone:614-293-8415Fax: (614) 293-4044
  • Molecular Biology and Cancer Genetics

General Research Interest

Exploring novel mechanisms of chemo- and radiosensitization in a variety of malignancies, as well as DNA damage response pathways in tumors and how this relates to therapeutic resistance. Other areas of interest include the role of stroma and tumor-microenvironment, and identifying molecular signatures which predict metastasis and response to radiation and molecularly-targeted therapies.

Research Description

Dr. Wiliams' laboratory research interests center around gastrointestinal (GI) malignancies, including pancreatic cancer. they are interested in the molecular biology and genetics of DNA damage response, and those pathways which dictate tumor aggressiveness such as invasion and metastasis, and those factors governing response to treatment from chemotherapy, molecularly-targeted agents, and radiation. He is also interested in the role of pancreatic stromal elements and their relationship to tumorigenesis, metastasis, and resistance to therapy. In addition, Dr. Williams has a strong interest in better understanding the role of Caveolin-1 (Cav-1) in aggressive neoplasms, such as pancreatic ductal carcinoma, glioblastoma, and renal cell carcinoma, which are neoplasms demonstrating a high degree of Cav-1 overexpression.

Current Publications

  • Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Christopher Ellison E, Bloomston M, Bekaii-Saab TNeoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas.Ann Surg Oncol in press 10/31/2014
  • Williams TM, Majithia L, Wang SJ, Thomas CR JrDefining the role of adjuvant therapy: cholangiocarcinoma and gall bladder cancer.Semin Radiat Oncol 24 94-104 4/1/2014
  • Williams TM, Nyati S, Ross BD, Rehemtulla AMolecular imaging of the ATM kinase activity.Int J Radiat Oncol Biol Phys 86 969-77 8/1/2013
  • Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM, Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LAA multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.Cancer 119 2692-700 8/1/2013
  • Williams TM, Maier ARole of stereotactic body radiation therapy and proton/carbon nuclei therapies.Cancer J 19 272-81 5/1/2013
  • Lawrence TS, Holland EC, Thomae TL, Chenevert TL, Rehemtulla A, Ross BD, Williams TM, Galbán S, Li F, Heist KA, Galbán CJDW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases.Transl Oncol 6 133-42 4/1/2013
  • Ru P, Williams TM, Chakravarti A, Guo DTumor metabolism of malignant gliomas.Cancers (Basel) 5 1469-84 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu